PET-CT for Gallbladder — and Bile Duct Cancer

Most cancer cells consume more glucose than normal cells — that is what PET detects. But some tumour types, including certain bile duct and gallbladder cancers, do not consume glucose at an elevated rate even when active. Well-differentiated and mucinous subtypes are particularly prone to this. The result is that PET may return a normal-looking scan on a tumour that other imaging clearly shows. This is why your team will never base a staging decision on PET alone in these cancers.

Yes, it can — and that is the main reason it is requested. If PET finds spread to distant sites not visible on CT, it changes the goal of treatment from attempting surgical cure to controlling the disease. It can also confirm what CT already suggested. What it cannot do is rule out all spread, particularly along the lining of the abdomen or in tumours with low FDG uptake. A normal PET in this cancer still requires the other scans to make a complete picture.

MRCP stands for magnetic resonance cholangiopancreatography. It is a type of MRI that shows the bile duct system in detail — where the tumour is, how far it extends along the duct, and which blood vessels are involved. None of that is visible on PET. These are exactly the questions a surgeon needs answered before deciding whether an operation is possible. ESMO and NCCN guidance treats MRI with MRCP as the primary local-staging tool for bile duct cancers.

Not necessarily — that decision is made by your oncologist and surgical team together, not by any one scan. Spread to nearby lymph nodes is sometimes still treated surgically in selected patients. Spread to distant organs generally shifts the approach away from surgery, but the decision also depends on your fitness and whether treatment has changed the picture. Ask your team to explain what the specific PET finding means for your situation, not what it means in general.

There is no fixed schedule that applies to everyone. PET is typically done as part of initial staging and may be repeated to assess response to chemotherapy before a decision about surgery. It is not used as frequently for routine monitoring in bile duct and gallbladder cancer as in some other cancers, partly because of the known limitations with FDG uptake in these tumour types. Your oncologist will explain when they plan to use it and what question they are trying to answer each time.

You can ask, and your oncologist will explain their reasoning. In some situations, MRI and CT have already given the team the information they need, making PET unlikely to add anything useful. Requesting a scan that will not change the treatment plan adds cost and a small radiation dose without benefit. If you feel the staging is incomplete, or you want a second opinion on the imaging approach, that is a reasonable request to make directly to your oncologist.